Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 5/20 | 0.80 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.71 |
| ▸ | CA1 | P00915 | 2/20 | 0.64 |
| ▸ | CA2 | P00918 | 2/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9941851 | 0.89 | CA9 (1.00) | CA9CHRNA7CA1CA2PTGS2 | |
| SCHEMBL6343758 | 0.85 | CA9 (1.00) | CA9CHRNA7CA1CA2PTGS2 | |
| SCHEMBL16876814 | 0.84 | CA9 (0.56) | CA9CHRNA7 | |
| SCHEMBL16876862 | 0.83 | CA9 (0.55) | CA9CHRNA7 | |
| SCHEMBL16876837 | 0.83 | FAAH (0.58) | CA9CHRNA7PTGS2PTGS1SMN1; SMN2 | |
| SCHEMBL6342008 | 0.83 | CHRNA7 (1.00) | CA9CHRNA7PTGS2SMN1; SMN2 | |
| SCHEMBL3100173 | 0.83 | CHRNA7 (1.00) | CA9CHRNA7CA1CA2PTGS2 | |
| SCHEMBL16876803 | 0.82 | CA9 (0.54) | CA9CHRNA7PTGS2 | |
| SCHEMBL18353705 | 0.82 | CA9 (0.53) | CA9CHRNA7 | |
| SCHEMBL3109354 | 0.82 | PTGS2 (0.77) | CA9CA1CA2PTGS2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | CA2, CA7, CA9 | CA9 3/4885CHRNA7 3165/4885CA1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.